Avalide: Comprehensive Blood Pressure Control in One Tablet
| Product dosage: 162.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.21 | $66.27 (0%) | 🛒 Add to cart |
| 60 | $1.67 | $132.54 $100.41 (24%) | 🛒 Add to cart |
| 90 | $1.48 | $198.80 $133.54 (33%) | 🛒 Add to cart |
| 120 | $1.39 | $265.07 $166.67 (37%) | 🛒 Add to cart |
| 180 | $1.30 | $397.61 $233.95 (41%) | 🛒 Add to cart |
| 270 | $1.24
Best per pill | $596.41 $334.35 (44%) | 🛒 Add to cart |
Synonyms | |||
Avalide combines two proven antihypertensive agents—irbesartan and hydrochlorothiazide—into a single, convenient tablet designed for patients requiring multiple medications to achieve blood pressure targets. This fixed-dose combination therapy leverages the complementary mechanisms of an angiotensin II receptor blocker (ARB) and a thiazide diuretic to provide synergistic effects on vascular tone and fluid balance. Clinical studies demonstrate superior efficacy compared to monotherapy, with significant reductions in both systolic and diastolic readings. Appropriate for stage 1 or 2 hypertension management, Avalide simplifies treatment regimens while supporting long-term cardiovascular risk reduction through consistent, 24-hour coverage.
Features
- Contains irbesartan (75 mg, 150 mg, or 300 mg) and hydrochlorothiazide (12.5 mg)
- Once-daily oral administration
- Available in multiple strength combinations for tailored dosing
- Film-coated tablets for ease of swallowing
- Manufactured under strict pharmaceutical quality standards
- Stable at room temperature with no special handling requirements
Benefits
- Achieves significant and sustained reductions in both systolic and diastolic blood pressure
- Simplifies medication regimen by combining two agents into one tablet, improving adherence
- Provides complementary mechanisms of action for enhanced efficacy in difficult-to-treat hypertension
- Supports long-term cardiovascular protection through consistent blood pressure control
- Reduces fluid retention-related symptoms through diuretic action
- Minimizes hypokalemia risk compared to thiazide monotherapy due to irbesartan’s potassium-sparing effect
Common use
Avalide is indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents, in patients for whom combination therapy is appropriate. It is particularly useful for patients who have not achieved adequate blood pressure control with monotherapy. The medication may be prescribed as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, especially those with stage 2 hypertension or above-target readings despite lifestyle modifications. Healthcare providers often consider Avalide for patients who would benefit from both volume reduction and renin-angiotensin system blockade.
Dosage and direction
The recommended starting dose is one tablet daily, containing irbesartan 150 mg/hydrochlorothiazide 12.5 mg. Dosage may be titrated after 2-4 weeks based on blood pressure response, up to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg daily. Patients already stabilized on the individual components may be switched to the corresponding combination tablet. Administration should occur at approximately the same time each day, with or without food. Tablet should be swallowed whole with a glass of water; do not crush or chew. Dose adjustment may be necessary for elderly patients or those with renal impairment.
Precautions
Monitor renal function and electrolytes periodically, particularly during initial therapy and after dosage adjustments. Assess volume status in patients with impaired renal function, heart failure, or cirrhosis. Use caution in patients with severe hepatic impairment. May cause photosensitivity reactions; advise sun protection measures. Orthostatic hypotension may occur, especially in volume-depleted patients. Monitor for signs of fluid or electrolyte imbalance including hypokalemia, hyponatremia, and hypomagnesemia. Regular blood pressure measurements are essential to evaluate therapeutic response. Not recommended during pregnancy due to potential fetal harm.
Contraindications
Hypersensitivity to irbesartan, hydrochlorothiazide, other sulfonamide-derived drugs, or any component of the formulation. Anuria. Concomitant use with aliskiren in patients with diabetes. Severe hepatic impairment. Refractory hypokalemia. Hypercalcemia. Patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
Possible side effects
Common adverse reactions (≥2%) include dizziness, fatigue, musculoskeletal pain, nausea/vomiting, and orthostatic hypotension. Less frequent side effects may include hyperkalemia, hypokalemia, hyponatremia, increased blood urea nitrogen, elevated creatinine, headache, rash, and upper respiratory infection. Rare but serious adverse effects include angioedema, acute renal failure, pancreatitis, hepatic impairment, and severe dermatological reactions. Thiazide component may cause glucose intolerance, hyperuricemia, and hypercalcemia. Some patients may experience decreased libido or erectile dysfunction.
Drug interaction
Concurrent use with other antihypertensive agents may potentiate blood pressure lowering effects. NSAIDs may reduce antihypertensive effectiveness and increase risk of renal impairment. Lithium levels may increase with thiazide diuretics. Potassium-sparing diuretics or potassium supplements may increase risk of hyperkalemia. Enhanced hypotensive effect with alcohol, barbiturates, or narcotics. Thiazides may increase responsiveness to nondepolarizing muscle relaxants. May alter insulin requirements in diabetic patients. Colestipol or cholestyramine may reduce absorption of hydrochlorothiazide.
Missed dose
If a dose is missed, take it as soon as remembered on the same day. If it is near the time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Maintain consistent timing of administration to ensure stable blood pressure control throughout the 24-hour period.
Overdose
Symptoms may include hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, electrolyte disturbances, and renal impairment. Primary manifestations result from excessive pharmacologic effects. Treatment involves supportive care with volume expansion using normal saline for hypotension. Hemodialysis may remove both components. Monitor electrolytes and renal function closely. Symptomatic treatment for specific manifestations should be instituted under medical supervision.
Storage
Store at room temperature (20-25°C or 68-77°F) in the original container. Protect from light and moisture. Keep tightly closed. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly dispose of unused medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare providers should exercise professional judgment when prescribing Avalide, considering individual patient factors, contraindications, and potential adverse effects. Patients should not adjust dosage or discontinue medication without consulting their healthcare provider. Full prescribing information should be reviewed before initiation of therapy.
Reviews
Clinical trials demonstrate Avalide produces significant blood pressure reductions compared to placebo and component monotherapies. In controlled studies, over 70% of patients achieved target blood pressure goals with combination therapy. Patients report improved convenience and adherence with single-tablet regimen compared to multiple pills. Healthcare providers note effective control in previously difficult-to-treat hypertensive patients. Long-term data support maintained efficacy with consistent safety profile over treatment periods exceeding one year. Real-world evidence confirms trial findings regarding both efficacy and tolerability in diverse patient populations.